Key Highlights
- Revenue was USD 12.87 million, against an estimate of USD 14.62 million.
- Net loss per share was USD 0.81, against an estimate of a USD 0.72 loss.
- Net loss widened to USD 23.72 million from USD 18.70 million.
- Cash and marketable securities totaled USD 194.5 million at September 30, 2026.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotechnology Business that develops small molecule medicines for viral infections and immunological conditions, posted total Revenue of USD 12.9 million for the fiscal fourth quarter ended September 30, 2026. That compared with USD 15.1 million a year earlier and an estimate of USD 14.62 million. Basic and diluted net loss per share was USD 0.81, compared with USD 0.87, against an estimate of a USD 0.72 loss, while the net loss was USD 23.72 million, compared with USD 18.70 million.
Royalties Behind the Revenue
All revenue was Royalty income earned on global net sales of MAVYRET/MAVIRET, the hepatitis C virus regimen of AbbVie (NYSE:ABBV). The company said the fall in quarterly and annual revenue stemmed from lower sales of that regimen. OMERS is entitled to 54.5% of ongoing royalty revenue under a royalty sale transaction, which is accounted for as Debt for reporting purposes.
Fourth Quarter Costs
Research and development expenses were USD 26.1 million, compared with USD 23.8 million, which the company linked to heavier clinical trial spending on its RSV programs, among them the RESOLVE and LOTUS studies. General and administrative expenses fell to USD 8.8 million from USD 9.7 million as stock-based compensation and legal costs from its Patent suit against Pfizer (NYSE:PFE) both declined.
Interest expense was USD 3.5 million, compared with USD 2.4 million, and interest and Investment income, net, was USD 1.8 million, compared with USD 2.1 million. The loss from operations was USD 22.04 million, compared with USD 18.39 million.
The Twelve Months to September 30, 2026
Total revenue for the year was USD 63.0 million, compared with USD 65.3 million. Research and Development expenses were USD 88.5 million, compared with USD 106.7 million, a drop the company explained by the timing of RSV clinical trial spending, partly offset by heavier costs in its immunology programs. General and administrative expenses were USD 36.8 million, compared with USD 43.9 million.
The loss from operations for the year was USD 62.38 million, compared with USD 85.35 million, and the net loss was USD 68.25 million, compared with USD 81.89 million. Basic and diluted net loss per share for the year was USD 2.35, compared with USD 3.84.
Pipeline Milestones, Leadership and Cash
The company completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients with RSV, with topline data anticipated in the first quarter of 2027. It also began dosing in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe RSV outcomes, with topline Phase 2b data anticipated in 2027. Topline Phase 1 data for EDP-978, an oral KIT inhibitor, is expected in the first quarter of 2027, and an IND filing for EDP-903, an oral STAT6 inhibitor, in the second quarter of 2027. EPS-5336 was selected as an MRGPRX2 development candidate, with an IND filing targeted for the fourth quarter of 2027.
The company announced the planned retirement of its President and CEO by February 2027 and the promotion of Tara L. Kieffer, Ph.D. to Chief Operating Officer. Cash and marketable securities totaled USD 194.5 million at September 30, 2026, and the company expects that cash runway to fund operations into fiscal 2029. Cash and cash equivalents were USD 20.27 million and short-term marketable securities were USD 174.24 million. Total Assets were USD 275.58 million, total liabilities were USD 195.38 million and total stockholders' Equity was USD 80.20 million.






Please wait processing your request...